Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

A new study from Turkey has raised questions about the potential effects of the Pfizer-BioNTech COVID-19 vaccine on eye health, revealing changes in the cornea’s inner layer that may signal stress or ...

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5, Comirnaty JN.1 and Comirnaty KP.2 may be administered concomitantly with a pneumococcal conjugated vaccine (PCV). an unadjuvanted ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202 ...

One chemistry tweak made mRNA vaccines dramatically safer and more effective—unlocking new potential for fighting disease.

The Trump administration is asking the Supreme Court to allow it to cut hundreds of millions of dollars’ worth of research ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

A new study reveals that Pfizer’s COVID-19 vaccine may cause subtle but measurable changes in the eyes — specifically in the ...